Gilead Sciences Acquires Arcellx for $7.8 Billion to Enhance Cancer Treatment Portfolio

Gilead Sciences has announced a definitive agreement to acquire Arcellx for up to $7.8 billion, marking its largest deal since 2020. The acquisition involves a cash payment of $115 per share, which represents a 68% premium over Arcellx's 30-day volume-weighted average share price. Additionally, Arcellx shareholders may receive a contingent value right (CVR) of $5 per share, contingent upon achieving cumulative global net sales of $6 billion for the experimental CAR-T therapy, anitocabtagene autoleucel (anito-cel), by the end of 2029. The deal is expected to close in the second quarter of 2026, pending regulatory approvals.

NasdaqGrafa logoGilead to buy Arcellx in $7.8bn dealGilead Sciences To Acquire Arcellx In $7.8 Billion Deal To Strengthen Cell Therapy Portfolio

Gilead's acquisition of Arcellx is primarily aimed at strengthening its oncology portfolio, particularly in the area of multiple myeloma treatment. Gilead has previously collaborated with Arcellx to co-develop anito-cel, which is currently under review by the U.S. Food and Drug Administration (FDA) as a fourth-line treatment for relapsed or refractory multiple myeloma. The FDA's decision is anticipated by December 23, 2026. Analysts believe that anito-cel could become a foundational treatment in this space, potentially outperforming existing therapies like Johnson & Johnson's Carvykti, which has achieved blockbuster status.

Fierce BiotechGilead to buy Arcellx in $7.8bn dealCNBCGilead Sciences To Acquire Arcellx In $7.8 Billion Deal To Strengthen Cell Therapy Portfolio

The acquisition is projected to be accretive to Gilead's earnings per share starting in 2028, contingent upon the successful approval and commercialization of anito-cel. Gilead's CEO, Daniel O'Day, emphasized the company's commitment to leveraging anito-cel's potential to benefit patients and enhance Gilead's position in oncology. The deal also allows Gilead to eliminate up to $1.5 billion in potential milestone payments associated with its prior partnership with Arcellx.

Fierce BiotechGilead Sciences To Acquire Arcellx In $7.8 Billion Deal To Strengthen Cell Therapy PortfolioBloombergGilead to buy Arcellx in $7.8bn deal

While the acquisition has been generally viewed favorably by analysts, some caution has been expressed regarding Gilead's timing and market position. RBC Capital Markets analyst Brian Abrahams noted that Gilead and Arcellx are behind competitors in the CAR-T therapy market, where early entrenchment is crucial. The degree of market acceptance for anito-cel in earlier lines of therapy remains uncertain, which could impact its commercial success.

BioPharmaDive

• “KEY QUOTES “This agreement reflects our conviction in the potential of anito-cel and our intention to move with speed so we can make the most of that potential for patients with multiple myeloma.” — Daniel O'Day, CEO, Gilead Sciences

Gilead Sciences To Acquire Arcellx In $7.8 Billion Deal To Strengthen Cell Therapy Portfolio

• “Beyond the potential launch this year, anito-cel could become a foundational treatment for multiple myeloma over time, including earlier lines of therapy.” — Daniel O'Day, CEO, Gilead Sciences

Fierce Biotech

The acquisition is expected to close in the second quarter of 2026, subject to regulatory approvals and customary conditions. Gilead's focus will be on advancing the development and commercialization of anito-cel, with the potential for significant impact on its oncology business and overall growth strategy.

Gilead Sciences To Acquire Arcellx In $7.8 Billion Deal To Strengthen Cell Therapy Portfolio